HYTN INNOVATIONS MMOED overview

VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“ HYTN ” or the “Company ”), a pharmaceutical company specializing in pharmaceutical-grade cannabis manufacturing is pleased to announce the receipt of an initial purchase order under manufacturing and pricing agreements (the Agreements) with SNDL Inc. (NASDAQ: SNDL) (" SNDL "), one of the world’s largest vertically integrated cannabis companies. This...

VANCOUVER, British Columbia, Dec. 16, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) ("HYTN" or "the Company"), a pharmaceutical company specializing in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce its successful export of cannabis to the United Kingdom’s 4C LABS. This announcement follows the news from November 28, 2024, that the Company received its...

VANCOUVER, British Columbia, Nov. 28, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or “the Company”), a pharmaceutical company specializing in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce the receipt of initial orders and import permits from the UK's 4C Labs, marking a significant milestone in their partnership. This achievement allows...

VANCOUVER, British Columbia, Nov. 08, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or “the Company”), a company specializing in the pharmaceutical development and production of psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce that it has engaged bullVestor Medien GmbH (“bullVestor”) (address: Gutenhofen 4, 4300, St. Valentin, Austria email: [email protected] ) to provide marketing...

VANCOUVER, British Columbia, Oct. 09, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN , FSE: 85W0 , OTC PINK: HYTNF ) (“ HYTN ” or “the Company ”), a pharmaceutical company specializing in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabis and psilocybin, proudly announces that it has received an additional Good Manufacturing Practices (“GMP”) certification for its Kelowna manufacturing facility. This certification...

VANCOUVER, British Columbia, Sept. 27, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or “the Company”), a pharmaceutical company specializing in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabinoids and psilocybin, is pleased to announce, further to its news release dated July 19, 2024, that it has filed a Business Acquisition Report (BAR) in respect of its acquisition of Prism...

VANCOUVER, British Columbia, Sept. 10, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or “the Company”), a pharmaceutical company specializing in the development, formulation, and manufacturing of psychoactive and psychotropic compounds, including cannabinoids and psilocybin, is proud to announce the establishment of international manufacturing and pricing agreements (the Agreements) with 4C LABS, a leading importer and distributor of...

VANCOUVER, British Columbia, July 29, 2024 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN | FSE: 85W0 | OTC PINK: HYTNF) “HYTN” or “the Company”, a pharmaceutical company specializing in the development, formulation, and manufacturing of products containing psychoactive and psychotropic compounds, including cannabis and psilocybin, is pleased to announce its approval for trading on the OTC PINK Market ("OTC PINK") effective July 29th, 2024, under the trading symbol “HYTNF”....